Patient demographics and clinical characteristics
Characteristic . | All patients (N = 32) . |
---|---|
Sex, M/F (%) | 14/18 (44/56) |
Age at MM diagnosis, median (range), y | 59 (46-77) |
Age at ALL/BALLP diagnosis, median (range), y | 65 (50-86) |
Time from MM to ALL/BALLLP, median (range), y | 5.5 (0.6-11.7) |
Length of lenalidomide exposure, median (range), mo | 41.8 (1.8-114.1) |
MM characteristics, n (%) | |
IgG heavy chain | 19 (59) |
IgA heavy chain | 8 (25) |
Unknown heavy chain | 3 (9) |
Light chain only MM | 2 (6) |
κ light chain | 19 (59) |
λ light chain | 12 (38) |
Unknown light chain | 1 (3) |
MM presentation, n (%) | |
Hypercalcemia | 2 (6) |
Renal insufficiency | 5 (16) |
Anemia | 9 (2) |
Bony lesions | 25 (7) |
CRAB criteria status unknown | 3 (9) |
Leptomeningeal disease | 1 (3) |
ALL/BALLLP lineage and presentation, n (%) | |
T-cell | 0 |
B-cell | 32 (100) |
Overt B-ALL at diagnosis | 29 (91) |
BALLLP at diagnosis | 3 (9) |
BCR::ABL-positive | 1 (3) |
BCR::ABL-negative | 31 (91) |
CD10 expression | 29 (91) |
CD20 expression | 18 (56) |
Low hypodiploidy∗ | 8 (31)† |
11q23 rearrangement‡ | 2 (8)† |
Characteristic . | All patients (N = 32) . |
---|---|
Sex, M/F (%) | 14/18 (44/56) |
Age at MM diagnosis, median (range), y | 59 (46-77) |
Age at ALL/BALLP diagnosis, median (range), y | 65 (50-86) |
Time from MM to ALL/BALLLP, median (range), y | 5.5 (0.6-11.7) |
Length of lenalidomide exposure, median (range), mo | 41.8 (1.8-114.1) |
MM characteristics, n (%) | |
IgG heavy chain | 19 (59) |
IgA heavy chain | 8 (25) |
Unknown heavy chain | 3 (9) |
Light chain only MM | 2 (6) |
κ light chain | 19 (59) |
λ light chain | 12 (38) |
Unknown light chain | 1 (3) |
MM presentation, n (%) | |
Hypercalcemia | 2 (6) |
Renal insufficiency | 5 (16) |
Anemia | 9 (2) |
Bony lesions | 25 (7) |
CRAB criteria status unknown | 3 (9) |
Leptomeningeal disease | 1 (3) |
ALL/BALLLP lineage and presentation, n (%) | |
T-cell | 0 |
B-cell | 32 (100) |
Overt B-ALL at diagnosis | 29 (91) |
BALLLP at diagnosis | 3 (9) |
BCR::ABL-positive | 1 (3) |
BCR::ABL-negative | 31 (91) |
CD10 expression | 29 (91) |
CD20 expression | 18 (56) |
Low hypodiploidy∗ | 8 (31)† |
11q23 rearrangement‡ | 2 (8)† |
F, female; M, male.
Includes patients with low hypodiploid features by traditional karyotyping (n = 5) or by FISH (n = 3).
Because low disease burden and/or lack of comprehensive cytogenetic data for 6 patients in the series, total evaluable patients here are considered as 26 rather than 32.
Refer to Discussion in the manuscript; possible but not definite in 1 of 2 patients.